Marc Beer is a co-founder, chairman, and chief executive officer at Renovia Inc., a private medical company based in Boston, United States. The company comes up with diagnostic and therapeutic devices that are to cure a variety of pelvic floor disorders. Marc Beer perused a Bachelor of Science degree in Miami University and has vast experience of more than twenty-five years in biotechnology, diagnostic and pharmaceuticals.
In early 2000, he became the founding chief executive of Via Cell, a firm that dealt with the umbilical cord stem cells. He led the firm into a rapid growth spurt such that in over a seven-year period, it became a robust commercial establishment. While Marc Beer was working here, he also served as a board member for Erytech Pharma, a biopharmaceutical company. He is also the founding chairperson of a privately held molecular diagnostic firm called Good Start Genetics, Inc. Marc Beer prides in him being a member of the Miami University Business consultative council, and a having a one-time membership of Notre Dame Research Consultative Committee. The erstwhile member of Mass Life Science Board also held marketing positions in Abbot Laboratories.
Renovia Inc. is passionate about women’s health and offers a personalized approach to the pelvic health of women. Its vision is to diagnose, cure and better the lives of those women affected by the pelvic floor disorders. It aims at moving forward with several upcoming products, developing a variety of diagnostic and curative products for the pelvic floor disorders.
The firm works together with the Longwood Fund an investment firm that is healthcare focused. Marc Beer recently raised $42M to fund women’s health. Bay Cross Capital Group, a consulting and advisory company that specializes in capital optimization and equity raises, advised Renovia Inc on its $42.3M financing. The funding consisted of $32.3 million in Series B equity and $10 million in venture debt. The funds gathered are aimed at developing and testing 4 more curative and diagnostic products not excluding a new cohort of the Leva device. Combining the companies creative and proprietary sensor applied sciences will give the customers valuable information to guide through new treatment options and bring better understanding and knowledge of the pelvic floor disorders eventually reducing the chronic healthcare costs.
Renovia’s technology assists in treatment through specific visualization of pelvic motion in real-time during pelvic floor muscle coaching, while observing usage and progress over time.
To achieve the company’s vision and mission, Marc Beer works with an able team of professionals with diverse qualifications and experience. The team includes William Dull, Dr. Samantha Pulliam, José Bohorquez, Ph.D., and Jessica McKinney. Renovia currently appointed John A. Fallon, M.D. to its board of directors. Learn more: https://people.equilar.com/bio/marc-beer-aegerion-pharmaceuticals-/salary/78453